Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aramchol for Dissolution of Cholesterol Gallstones
NCT02325492Phase 2Terminated
- Sponsor
- Galmed Pharmaceuticals
- Start
- Oct 2014
- Primary completion
- Oct 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of aramchol in cholelithiasis (3 arms), sponsored by Galmed Pharmaceuticals. Primary endpoint: Complete dissolution of existing gallstones proven by repeated US examined gallbladder at 12 weeks. Started Oct 2014; status: terminated.
02
Drugs
aramchol
03
Conditions
cholelithiasis
Beyond the preview
Go deeper on NCT02325492.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02325492.